Getinge AB ((GNGBY)) has held its Q1 earnings call. Read on for the main highlights of the call.
Getinge’s latest earnings call struck a cautiously upbeat tone as management balanced solid operational progress with clear near‑term pressures. Organic growth, healthier order intake, strong cash flow and key product approvals showcased momentum, but currency, tariffs and lingering quality costs weighed on reported margins, while weakness in Acute Care Therapies highlighted the company’s remaining execution risks.
Recurring and High-Margin Revenue Mix
Getinge underscored that recurring revenue, such as consumables and service, now accounts for roughly two‑thirds of total sales, providing greater resilience and visibility. Management added that high‑margin offerings are approaching 70% of the portfolio, indicating a successful shift away from lower‑margin products and supporting the long‑term profitability ambition.
Organic Top-Line and Order Intake Growth
Organic net sales in the first quarter grew a modest 0.8%, but the tone was more optimistic around demand indicators, with group order intake up 3.9% organically. Surgical Workflows delivered double‑digit order growth and Life Science also expanded, giving management confidence that the order book can support stronger revenue conversion as supply and logistics normalise.
Strong Cash Flow and Balance Sheet
Free cash flow reached SEK 842 million, helping lift cash to about SEK 4 billion and pushing net debt down to SEK 9.3 billion, or SEK 7.0 billion excluding pension liabilities. This translated into leverage of 1.5 times adjusted EBITDA, or 1.1 times on an ex‑pension basis, leaving Getinge comfortably below its internal 2.5 times ceiling and providing room for investment and potential bolt‑on deals.
Reported Adjusted EBITA and Underlying Margin Improvement
Adjusted EBITA came in at SEK 824 million, corresponding to a reported margin of 11.1% and appearing soft versus prior years on headline numbers. However, management stressed that excluding SEK 226 million of currency and tariff headwinds, the underlying adjusted EBITA margin would have been about 12.6%, pointing to real operational improvement despite the macro drag.
Quality Metrics Improving
The company highlighted a meaningful decline in field actions relative to sales, a key indicator for regulators and hospitals following past quality issues. This positive trend has continued into early 2026, reinforcing the view that remediation programmes are gaining traction and should, over time, translate into lower extraordinary quality costs and better operational stability.
Regulatory and Product Milestones
Getinge reported important milestones on the product front, including CE approval for Cardiohelp II, with a limited rollout in early second quarter and a full European launch planned for the beginning of the third quarter. The company also secured an EU MDR certificate for its Intergard Synergy antimicrobial vascular graft and introduced a new steam sterilizer for Life Science clients, broadening its offering in infection prevention and research.
ECLS and Sterile Transfer Momentum
Extracorporeal life support consumables continued to post broad‑based growth even against tough comparisons from prior periods, underlining robust clinical demand. In addition, BetaBags and other sterile transfer solutions gained further traction, supporting the company’s strategy to deepen its presence in high‑value consumables that complement installed equipment.
Operational Efficiency and Long-Term Targets
Working capital days improved to around 90, reflecting better inventory and receivables management, while the rolling 12‑month operating return on invested capital reached 11.4%, above the group’s cost of capital. Management reiterated its long‑term ambition for an adjusted EBITA margin of 16% to 19% by the end of 2028, signalling ongoing focus on productivity, pricing and mix improvements to lift returns.
Currency and Tariff Headwinds
Currency movements and tariffs exerted a combined SEK 226 million drag on adjusted EBITA in the quarter, with tariffs alone accounting for just over SEK 100 million. These factors reduced adjusted gross margin by 0.7 percentage points and shaved 0.3 percentage points off the EBITA margin, while also inflating operating expenses after currency effects, underscoring how external factors are temporarily masking internal progress.
Adjusted EBITA Margin Compression (Reported)
On a reported basis, the adjusted EBITA margin declined to 11.1%, representing visible compression versus comparable periods and drawing investor attention. Management argued that this should be seen primarily as the mechanical outcome of FX and tariff shocks rather than weakening execution, but acknowledged that reported margins will remain sensitive as long as these headwinds persist.
Acute Care Therapies Weakness
Acute Care Therapies was the clear soft spot, with order intake down and organic net sales declining, mainly due to very tough ventilator comparisons following a competitor exit last year. Further pressure came from delayed Cardiosave deliveries, which slipped into the second quarter and temporarily depressed both sales and orders, creating noise in assessing underlying demand.
Ongoing Elevated Quality-Related Costs
Extraordinary quality‑related costs remain a notable burden, having peaked at roughly SEK 800 million in 2024 and only slightly easing in 2025, according to management. While the company aims to at least halve these costs by 2027–2028, investors were reminded that remediation, monitoring and compliance spending will continue to weigh on margins in the near term even as incident metrics improve.
No Margin Guidance for 2026
Despite reaffirming its growth ambitions, Getinge declined to provide specific margin guidance for 2026, citing macro and geopolitical uncertainty as key reasons for the caution. This stance leaves some ambiguity around the pace of margin recovery, but the company pointed to its structural levers, such as mix, productivity and quality‑cost reductions, as underpinning the longer‑term profitability roadmap.
Geopolitical and Tariff Uncertainty
Management highlighted that geopolitical tensions, including those affecting the Middle East, and evolving tariff regimes remain important swing factors for the business and broader healthcare supply chains. While exposure to the region is limited at around 2% of sales, ongoing steel and component tariffs are still being assessed, leaving potential for further cost volatility and necessitating flexible sourcing and pricing strategies.
Pricing and Cost-Pass Through Limits
Price increases of roughly 2% are planned for 2026 and will be implemented gradually during the year, contributing modestly to margin support. However, management cautioned that surges in raw material or freight costs cannot automatically be passed through to customers, meaning sustained cost inflation would apply pressure to profitability if not offset by productivity or mix improvements.
Segment Disclosure Gaps
In a point that may frustrate some analysts, Getinge chose not to disclose detailed subsegment financials such as the specific earnings impact of ventilators or the EBITA for individual Acute Care Therapies categories. This limited transparency makes it harder to quantify the exact weight of certain headwinds and assess the underlying health of each niche, potentially adding a small governance discount in investors’ eyes.
Forward-Looking Guidance and Outlook
For 2026, Getinge reconfirmed its guidance of 3% to 5% organic net sales growth, adjusted for the planned phaseout of Surgical Perfusion, which is set to fall sharply from about SEK 250 million in 2025 to around SEK 50 million in 2026. The company also reiterated its long‑term adjusted EBITA margin target of 16% to 19% by 2028, pointing to solid free cash flow, a strengthened balance sheet, planned 2% price hikes and expected declines in extraordinary quality costs as key supports, while noting that margins could benefit if current FX and tariff drags ease.
Getinge’s earnings call paints a picture of a company in transition, with a stronger, more recurring revenue base and improving quality metrics set against external shocks and segment‑specific softness. For investors, the message is that operational momentum and balance sheet strength provide a solid foundation, but reported margins will remain a function of currencies, tariffs and remediation costs until the full benefits of the ongoing transformation are realised.
Trending Articles:
This story was written using TipRanks's AI tools and reviewed by a TipRanks editor.